EU/3/13/1208: Orphan designation for the treatment of Stargardt's disease



On 13 November 2013, orphan designation (EU/3/13/1208) was granted by the European Commission to Katairo GmbH, Germany, for soraprazan for the treatment of Stargardt's disease.

Key facts

Active substance
Intended use
Treatment of Stargardt's disease
Orphan designation status
EU designation number
Date of designation
Katairo GmbH
Lederstrasse 21
72127 Kusterdingen
Tel. +49 7071 5496184
Fax +49 7071 5496183

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating